Article(id=1326652803713446151, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652739800642340, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.05.015, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1732118400000, receivedDateStr=2024-11-21, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228276421, onlineDateStr=2026-11-09, pubDate=1746806400000, pubDateStr=2025-05-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228276421, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228276421, creator=13701087609, updateTime=1794228276421, updator=13701087609, issue=Issue{id=1326652739800642340, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='5', pageStart='429', pageEnd='528', issueExtLink='null', onlineDate='null', pubDate='1746806400000', pubDateStr='2025-05-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228261184, creator='13701087609', updateTime=1794273040769, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326840559311893443, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652739800642340, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326840559311893444, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652739800642340, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=516, endPage=522, ext={EN=ArticleExt(id=1326652805370196232, articleId=1326652803713446151, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Advances in pharmacokinetics and bioanalytical methods for proteolysis-targeting chimera, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Proteolysis-targeting chimera (PROTAC) is a new technology for targeting protein degradation that has received great attention in the biomedical science community. PROTAC molecules can quickly and efficiently deplete target proteins by inducing degradation of target proteins using the ubiquitin-protease system, and can bind to substrates again to achieve multiple ubiquitination reactions, optimizing the dose dependence and drug resistance of traditional small molecules to a certain extent. However, this unique chemical structure and mechanism of action also brings many challenges to its in vivo and in vitro pharmacokinetic studies, mainly including poor solubility, poor permeability, poor oral absorption, and low bioavailability. Starting from the analysis of the physicochemical properties of PROTAC molecules, this article analyzed the pharmacokinetic characteristics and summarized the bioanalysis methods of such drugs. It also discussed the challenges and prospects of PROTAC technology, providing a reference for innovative research and breakthroughs in the field of PROTAC drugs.

, authors=Yuxin WANG1, 2, 3, Zhiru XU1, 2, 3, *, authorsList=Yuxin WANG, Zhiru XU, authorCompany=null, correspAuthors=Zhiru XU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326652805709934857, articleId=1326652803713446151, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=蛋白降解靶向嵌合体分子药代动力学及其生物分析方法的研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

蛋白降解靶向嵌合体(proteolysis-targeting chimera,PROTAC)是一种靶向蛋白质降解的新技术,在生物医药领域受到极大关注。PROTAC分子通过泛素-蛋白酶体系诱导目标蛋白降解能快速、高效地耗竭靶蛋白,并可再次结合底物,实现多次泛素化反应,能一定程度上优化传统小分子表现的剂量依赖性。然而,这种独特化学结构及作用机制也给其体内外药代动力学研究带来诸多挑战,主要包括溶解度不佳、渗透性不好、口服吸收差及生物利用度低等。该文以PROTAC分子的物理化学性质为出发点,分析药代动力学特征,并概述此类药物的生物分析方法,讨论PROTAC技术面临的挑战和前景,为PROTAC药物领域的创新研发及难点突破提供参考。

, authors=王宇昕1, 2, 3, 徐智儒1, 2, 3, *, authorsList=王宇昕, 徐智儒, authorCompany=null, correspAuthors=徐智儒, authorNote=

王宇昕,硕士研究生,研究方向:药物代谢动力学、药物效应动力学。

, correspAuthorsNote=
徐智儒,博士,研究员,研究方向:新药临床前药物代谢动力学、中药药效物质基础研究、毒物相关的筛查及体内外代谢机制研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=S51huf3nTgMa44sua6eN4A==, magXml=lbrAZmaua0WYd+HftG/8Pw==, pdfUrl=null, pdf=wOwhZ4SBfCKV1U5yoK/yrQ==, pdfFileSize=882809, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=9d5RKJ99JeWXlaSQU+wjDw==, mapNumber=null, fund=null)}, authors=[Author(id=1326652806221639957, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652806368440601, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, authorId=1326652806221639957, language=EN, stringName=Yuxin WANG, firstName=Yuxin, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, address=1.China State Institute of Pharmaceutical Industry, Shanghai 201203, China
2.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry,Shanghai 200437, China
3.Shanghai Professional and Technical Service Center for Biological Material Druggability Evaluation, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652806435549466, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, authorId=1326652806221639957, language=CN, stringName=王宇昕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, address=1.中国医药工业研究总院,上海 201203
2.中国医药工业研究总院,上海医药工业研究院创新药物与制药工艺国家重点实验室,上海 200437
3.上海市生物物质成药性评价专业技术服务中心,上海 200437, bio={"content":"

王宇昕,硕士研究生,研究方向:药物代谢动力学、药物效应动力学。

"}, bioImg=null, bioContent=

王宇昕,硕士研究生,研究方向:药物代谢动力学、药物效应动力学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652805923844363, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=1., ext=[AuthorCompanyExt(id=1326652805936427276, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652805923844363, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326652805944815885, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652805923844363, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院,上海 201203)]), AuthorCompany(id=1326652806016119054, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=2., ext=[AuthorCompanyExt(id=1326652806049673487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806016119054, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry,Shanghai 200437, China), AuthorCompanyExt(id=1326652806058062096, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806016119054, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业研究总院,上海医药工业研究院创新药物与制药工艺国家重点实验室,上海 200437)]), AuthorCompany(id=1326652806154531089, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=3., ext=[AuthorCompanyExt(id=1326652806162919698, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806154531089, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Shanghai Professional and Technical Service Center for Biological Material Druggability Evaluation, Shanghai 200437, China), AuthorCompanyExt(id=1326652806171308307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806154531089, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.上海市生物物质成药性评价专业技术服务中心,上海 200437)])]), Author(id=1326652806502658332, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652806590738720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, authorId=1326652806502658332, language=EN, stringName=Zhiru XU, firstName=Zhiru, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, *, address=1.China State Institute of Pharmaceutical Industry, Shanghai 201203, China
2.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry,Shanghai 200437, China
3.Shanghai Professional and Technical Service Center for Biological Material Druggability Evaluation, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652806708179233, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, authorId=1326652806502658332, language=CN, stringName=徐智儒, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, *, address=1.中国医药工业研究总院,上海 201203
2.中国医药工业研究总院,上海医药工业研究院创新药物与制药工艺国家重点实验室,上海 200437
3.上海市生物物质成药性评价专业技术服务中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652805923844363, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=1., ext=[AuthorCompanyExt(id=1326652805936427276, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652805923844363, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326652805944815885, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652805923844363, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院,上海 201203)]), AuthorCompany(id=1326652806016119054, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=2., ext=[AuthorCompanyExt(id=1326652806049673487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806016119054, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry,Shanghai 200437, China), AuthorCompanyExt(id=1326652806058062096, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806016119054, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业研究总院,上海医药工业研究院创新药物与制药工艺国家重点实验室,上海 200437)]), AuthorCompany(id=1326652806154531089, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=3., ext=[AuthorCompanyExt(id=1326652806162919698, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806154531089, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Shanghai Professional and Technical Service Center for Biological Material Druggability Evaluation, Shanghai 200437, China), AuthorCompanyExt(id=1326652806171308307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806154531089, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.上海市生物物质成药性评价专业技术服务中心,上海 200437)])])], keywords=[Keyword(id=1326652806892728610, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, language=EN, orderNo=1, keyword=proteolysis-targeting chimera), Keyword(id=1326652807010169123, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, language=EN, orderNo=2, keyword=pharmacokinetics), Keyword(id=1326652807094055204, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, language=EN, orderNo=3, keyword=bioanalytical methods), Keyword(id=1326652807148581157, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, language=CN, orderNo=1, keyword=蛋白降解靶向嵌合体), Keyword(id=1326652807253438758, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, language=CN, orderNo=2, keyword=药代动力学), Keyword(id=1326652807333130536, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, language=CN, orderNo=3, keyword=生物分析方法)], refs=[Reference(id=1326652807408628009, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=ZENG SX, YE YQ, XIA HY, et al. Current advances and development strategies of orally bioavailable PROTACs[J].Eur J Med Chem, 2023, 261: 115793., articleTitle=null, refAbstract=null), Reference(id=1326652807492514090, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=LI X, SONG YC. Proteolysis-targeting chimera(PROTAC)for targeted protein degradation and cancer therapy[J]. J Hematol Oncol, 2020, 13(1): 50., articleTitle=null, refAbstract=null), Reference(id=1326652807555428651, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=王熙敏, 张程亮, 陈云舟. 靶向蛋白降解技术的特点与研究进展[J]. 中国医院药学杂志, 2023, 43(10): 1170-1175., articleTitle=null, refAbstract=null), Reference(id=1326652807618343212, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Price E, Weinheimer M, Rivkin A, et al. Beyond rule of five and PROTACs in modern drug discovery: polarity reducers, chameleonicity, and the evolving physicochemical landscape[J]. J Med Chem, 2024, 67(7): 5683-5698., articleTitle=null, refAbstract=null), Reference(id=1326652807693840685, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=GE JX, LI SM, WENG GQ, et al. PROTAC-DB 3.0:an updated database of PROTACs with extended pharmacokinetic parameters[J]. Nucleic Acids Res, 2025,53(D1): D1510-D1515., articleTitle=null, refAbstract=null), Reference(id=1326652807769338158, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=BHUMIREDDY A, BANDARU NVMR, REDDY BR, et al. Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders[J]. Bioorg Med Chem Lett,2022, 55: 128448., articleTitle=null, refAbstract=null), Reference(id=1326652807840641327, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=HAN X, ZHAO LJ, XIANG WG, et al. Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer[J]. J Med Chem, 2021, 64(17):12831-12854., articleTitle=null, refAbstract=null), Reference(id=1326652807916138800, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=KIM GY, SONG CW, YANG YS, et al. Chemical degradation of androgen receptor(AR) using bicalutamide analog-thalidomide PROTACs[J]. Molecules, 2021, 26(9): 2525., articleTitle=null, refAbstract=null), Reference(id=1326652807987441969, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=CECCHINI C, TARDY S, SCAPOZZA L. Linkers as game-changers in PROTAC technology: Emphasizing general trends in PROTAC pharmacokinetics for their rational design[J].Chimia(Aarau), 2022, 76(4): 341-345., articleTitle=null, refAbstract=null), Reference(id=1326652809686135090, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=CANTRILL C, CHATURVEDI P, RYNN C. Fundamental aspects of DMPK optimization of targeted protein degraders[J]. Drug Discov Today, 2020, 25(6): 969-982., articleTitle=null, refAbstract=null), Reference(id=1326652809761632564, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=REJ R K, ALLU S R, ROY J, et al. Orally bioavailable proteolysis-targeting chimeras: an innovative approach in the golden era of discovering small-molecule cancer drugs[J].Pharmaceuticals(Basel), 2024, 17(4): 494., articleTitle=null, refAbstract=null), Reference(id=1326652809816158517, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG YT, PRICE E, FENG M, et al. High-throughput SFC-MS/MS method to measure EPSA and predict human permeability[J]. J Med Chem, 2024, 67(16): 13765-13777., articleTitle=null, refAbstract=null), Reference(id=1326652809900044598, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=ERMONDI G, JIMENEZ DG, SEBASTIANO MR, et al.Rational control of molecular properties is mandatory to exploit the potential of PROTACs as oral drugs[J]. ACS Med Chem Lett, 2021, 12(7): 1056-1060., articleTitle=null, refAbstract=null), Reference(id=1326652809958764855, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=MAPLE HJ, CLAYDEN N, BARON A, et al. Developing degraders: principles and perspectives on design and chemical space[J]. Med Chem Comm, 2019, 10(10): 1755-1764., articleTitle=null, refAbstract=null), Reference(id=1326652810017485112, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=EDMONDSON S D, YANG B, FALLAN C. Proteolysis targeting chimeras(PROTACs) in " beyond rule-of-five"chemical space: recent progress and future challenges[J].Bioorg Med Chem Lett, 2019, 29(13): 1555-1564., articleTitle=null, refAbstract=null), Reference(id=1326652810072011065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=JIMENEZ DG, SEBASTIANO MR, VALLARO M, et al.IMHB-Mediated chameleonicity in drug design: a focus on structurally related PROTACs[J]. J Med Chem, 2024,67(13): 11421-11434., articleTitle=null, refAbstract=null), Reference(id=1326652810130731322, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=HAN X, WANG C, QIN C, et al. Discovery of ARD-69 as a highly potent proteolysis targeting chimera(PROTAC)degrader of androgen receptor(AR) for the treatment of prostate cancer[J]. J Med Chem, 2019, 62(2): 941-964., articleTitle=null, refAbstract=null), Reference(id=1326652810189451579, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=MARES A, MIAH AH, SMITH IED, et al. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2[J]. Commun Biol, 2020,3(1): 140., articleTitle=null, refAbstract=null), Reference(id=1326652810252366140, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=WEI MM, ZHAO R, CAO YT, et al. First orally bioavailable prodrug of proteolysis targeting chimera(PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo[J]. Eur J Med Chem,2021, 209: 112903., articleTitle=null, refAbstract=null), Reference(id=1326652810344640829, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=ZOU ZF, YANG L, NIE HJ, et al. Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy[J]. Acta Pharmacol Sin, 2024,45(8): 1740-1751., articleTitle=null, refAbstract=null), Reference(id=1326652810411749694, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=YANG WZ, GADGIL P, KRISHNAMURTHY VR, et al. The evolving druggability and developability space: Chemically modified new modalities and emerging small molecules[J].AAPS J, 2020, 22(2): 21., articleTitle=null, refAbstract=null), Reference(id=1326652810470469951, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=VOLAK LP, DUEVEL HM, HUMPHREYS S, et al.Industry perspective on the pharmacokinetic and absorption,distribution, metabolism, and excretion characterization of heterobifunctional protein degraders[J]. Drug Metab Dispos,2023, 51(7): 792-803., articleTitle=null, refAbstract=null), Reference(id=1326652810537578816, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=RICCARDI K, CAWLEY S, YATES PD, et al. Plasma protein binding of challenging compounds[J]. J Pharm Sci, 2015,104(8): 2627-2636., articleTitle=null, refAbstract=null), Reference(id=1326652810629853505, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=SEVERINI LL, BUFALIERI F, INFANTE P, et al.Proteolysis-targeting chimera(PROTAC): Is the technology looking at the treatment of brain tumors?[J]. Front Cell Dev Biol, 2022, 10: 854352., articleTitle=null, refAbstract=null), Reference(id=1326652810701156674, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=KURIMCHAK AM, HERRERA-MONTAVEZ C,MONTSERRAT-SANGRA S, et al. The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells[J]. Sci Signal, 2022, 15(749):eabn2707., articleTitle=null, refAbstract=null), Reference(id=1326652810785042755, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG NY, HOU DY, HU XJ, et al. Nano proteolysis targeting chimeras(PROTACs) with anti-hook effect for tumor therapy[J]. Angew Chem Int Ed Engl, 2023, 62(37):e202308049., articleTitle=null, refAbstract=null), Reference(id=1326652810847957316, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=XU KX, WANG Z, XIANG ST, et al. Characterizing the cooperative effect of PROTAC systems with end-point binding free energy calculation[J]. J Chem Inf Model, 2024,64(19): 7666-7678., articleTitle=null, refAbstract=null), Reference(id=1326652810952814917, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=HALLIFAX D, TURLIZZI E, ZANELLI U, et al. Clearance-dependent underprediction of in vivo intrinsic clearance from human hepatocytes: comparison with permeabilities from artificial membrane(PAMPA) assay, in silico and caco-2 assay, for 65 drugs[J]. Eur J Pharm Sci, 2012, 45(5): 570-574., articleTitle=null, refAbstract=null), Reference(id=1326652811040895302, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=GORACCI L, DESANTIS J, VALERI A, et al.Understanding the metabolism of proteolysis targeting chimeras (PROTACs): The next step toward pharmaceutical applications[J]. J Med Chem, 2020, 63(20): 11615-11638., articleTitle=null, refAbstract=null), Reference(id=1326652811112198471, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=XU MS, GU XF, LI C, et al. A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects[J]. Acta Pharmacol Sin, 2024,45(10): 2174-2185., articleTitle=null, refAbstract=null), Reference(id=1326652811183501640, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG DL, MA B, DRAGOVICH PS, et al. Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs[J]. Commun Med(Lond), 2024,4(1): 87., articleTitle=null, refAbstract=null), Reference(id=1326652811275776329, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=NGUYEN TTL, KIM JW, CHOI HI, et al. Development of an LC-MS/MS method for ARV-110, a PROTAC molecule, and applications to pharmacokinetic studies[J]. Molecules, 2022,27(6): 1977., articleTitle=null, refAbstract=null), Reference(id=1326652811355468106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=NIESSEN J, NILSSON JM, PETERS K, et al.Development and validation of LC-MS/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide(ARV-110) and vepdegestrant(ARV-471)[J]. J Pharm Biomed Anal, 2024, 249: 116348., articleTitle=null, refAbstract=null), Reference(id=1326652811422576971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG Y, WANG ZY, WANG XW, et al. Establishment and validation of a sensitive LC-MS/MS method for the quantification of KRAS G12C protein PROTAC molecule LC-2 in rat plasma and its application to in vivo pharmacokinetic studies of LC-2 PEGylated liposomes[J].Biomed Chromatogr, 2023, 37(6): e5629., articleTitle=null, refAbstract=null), Reference(id=1326652811514851660, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=王鹏伟. PROTACs前体化合物的合成研究[D]. 湘潭: 湘潭大学, 2021., articleTitle=null, refAbstract=null), Reference(id=1326652811586154829, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=KANG LJ, WENG ND, JIAN WY. LC-MS bioanalysis of intact proteins and peptides[J]. Biomed Chromatogr, 2020,34(1): e4633., articleTitle=null, refAbstract=null), Reference(id=1326652811653263694, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=ROY MJ, WINKLER S, HUGHES SJ, et al. SPR-Measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate[J]. ACS Chem Biol, 2019, 14(3):361-368., articleTitle=null, refAbstract=null), Reference(id=1326652811720372559, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=RICHING KM, MAHAN S, CORONA CR, et al. Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action[J]. ACS Chem Biol, 2018, 13(9):2758-2770., articleTitle=null, refAbstract=null), Reference(id=1326652811779092816, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=KOZIOLEK M, AUGUSTIJNS P, BERGER C, et al.Challenges in permeability assessment for oral drug product development[J]. Pharmaceutics, 2023, 15(10): 2397., articleTitle=null, refAbstract=null), Reference(id=1326652811837813073, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=VERMA S, MANNA D. Controlling PROTACs with light[J].Chem Med Chem, 2020, 15(14): 1258-1261., articleTitle=null, refAbstract=null), Reference(id=1326652811913310546, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=LEE M, WU JP, LEE J, et al. A chiral pool strategy for the synthesis of a SMARCA2 degrading PROTAC[J]. Org Pro Res Dev, 2024, 28(4): 1239-1252., articleTitle=null, refAbstract=null), Reference(id=1326652811976225107, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=MALARVANNAN M, RAVICHANDIRAN V, PAUL D.Advances in analytical technologies for emerging drug modalities and their separation challenges in LC-MS systems[J]. J Chromatogr A, 2024, 1732: 465226., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1326652805923844363, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=1., ext=[AuthorCompanyExt(id=1326652805936427276, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652805923844363, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326652805944815885, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652805923844363, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院,上海 201203)]), AuthorCompany(id=1326652806016119054, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=2., ext=[AuthorCompanyExt(id=1326652806049673487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806016119054, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry,Shanghai 200437, China), AuthorCompanyExt(id=1326652806058062096, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806016119054, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业研究总院,上海医药工业研究院创新药物与制药工艺国家重点实验室,上海 200437)]), AuthorCompany(id=1326652806154531089, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=3., ext=[AuthorCompanyExt(id=1326652806162919698, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806154531089, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Shanghai Professional and Technical Service Center for Biological Material Druggability Evaluation, Shanghai 200437, China), AuthorCompanyExt(id=1326652806171308307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806154531089, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.上海市生物物质成药性评价专业技术服务中心,上海 200437)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.05.015, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.05.015, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.05.015, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.05.015, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1746806400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
蛋白降解靶向嵌合体分子药代动力学及其生物分析方法的研究进展
王宇昕 1, 2, 3 , 徐智儒 1, 2, 3, *
世界临床药物 | 综述评论 2025,46(5): 516-522
收起
收藏切换
世界临床药物 |综述评论 2025 , 46 (5) : 516 -522
蛋白降解靶向嵌合体分子药代动力学及其生物分析方法的研究进展
全屏
[Author(id=1326652806221639957, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652806368440601, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, authorId=1326652806221639957, language=EN, stringName=Yuxin WANG, firstName=Yuxin, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, address=1.China State Institute of Pharmaceutical Industry, Shanghai 201203, China
2.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry,Shanghai 200437, China
3.Shanghai Professional and Technical Service Center for Biological Material Druggability Evaluation, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652806435549466, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, authorId=1326652806221639957, language=CN, stringName=王宇昕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, address=1.中国医药工业研究总院,上海 201203
2.中国医药工业研究总院,上海医药工业研究院创新药物与制药工艺国家重点实验室,上海 200437
3.上海市生物物质成药性评价专业技术服务中心,上海 200437, bio={"content":"

王宇昕,硕士研究生,研究方向:药物代谢动力学、药物效应动力学。

"}, bioImg=null, bioContent=

王宇昕,硕士研究生,研究方向:药物代谢动力学、药物效应动力学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652805923844363, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=1., ext=[AuthorCompanyExt(id=1326652805936427276, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652805923844363, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326652805944815885, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652805923844363, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院,上海 201203)]), AuthorCompany(id=1326652806016119054, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=2., ext=[AuthorCompanyExt(id=1326652806049673487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806016119054, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry,Shanghai 200437, China), AuthorCompanyExt(id=1326652806058062096, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806016119054, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业研究总院,上海医药工业研究院创新药物与制药工艺国家重点实验室,上海 200437)]), AuthorCompany(id=1326652806154531089, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=3., ext=[AuthorCompanyExt(id=1326652806162919698, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806154531089, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Shanghai Professional and Technical Service Center for Biological Material Druggability Evaluation, Shanghai 200437, China), AuthorCompanyExt(id=1326652806171308307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806154531089, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.上海市生物物质成药性评价专业技术服务中心,上海 200437)])]), Author(id=1326652806502658332, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652806590738720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, authorId=1326652806502658332, language=EN, stringName=Zhiru XU, firstName=Zhiru, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, *, address=1.China State Institute of Pharmaceutical Industry, Shanghai 201203, China
2.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry,Shanghai 200437, China
3.Shanghai Professional and Technical Service Center for Biological Material Druggability Evaluation, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652806708179233, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, authorId=1326652806502658332, language=CN, stringName=徐智儒, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, *, address=1.中国医药工业研究总院,上海 201203
2.中国医药工业研究总院,上海医药工业研究院创新药物与制药工艺国家重点实验室,上海 200437
3.上海市生物物质成药性评价专业技术服务中心,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652805923844363, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=1., ext=[AuthorCompanyExt(id=1326652805936427276, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652805923844363, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326652805944815885, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652805923844363, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院,上海 201203)]), AuthorCompany(id=1326652806016119054, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=2., ext=[AuthorCompanyExt(id=1326652806049673487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806016119054, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry,Shanghai 200437, China), AuthorCompanyExt(id=1326652806058062096, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806016119054, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医药工业研究总院,上海医药工业研究院创新药物与制药工艺国家重点实验室,上海 200437)]), AuthorCompany(id=1326652806154531089, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, xref=3., ext=[AuthorCompanyExt(id=1326652806162919698, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806154531089, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Shanghai Professional and Technical Service Center for Biological Material Druggability Evaluation, Shanghai 200437, China), AuthorCompanyExt(id=1326652806171308307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652803713446151, companyId=1326652806154531089, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.上海市生物物质成药性评价专业技术服务中心,上海 200437)])])]
王宇昕1, 2, 3, 徐智儒1, 2, 3, *
作者信息
  • 1.中国医药工业研究总院,上海 201203
  • 2.中国医药工业研究总院,上海医药工业研究院创新药物与制药工艺国家重点实验室,上海 200437
  • 3.上海市生物物质成药性评价专业技术服务中心,上海 200437
通讯作者:
徐智儒,博士,研究员,研究方向:新药临床前药物代谢动力学、中药药效物质基础研究、毒物相关的筛查及体内外代谢机制研究。
作者简介:

王宇昕,硕士研究生,研究方向:药物代谢动力学、药物效应动力学。

Advances in pharmacokinetics and bioanalytical methods for proteolysis-targeting chimera
Yuxin WANG1, 2, 3, Zhiru XU1, 2, 3, *
Affiliations
  • 1.China State Institute of Pharmaceutical Industry, Shanghai 201203, China
  • 2.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry,Shanghai 200437, China
  • 3.Shanghai Professional and Technical Service Center for Biological Material Druggability Evaluation, Shanghai 200437, China
出版时间: 2025-05-10 doi: 10.13683/j.wph.2025.05.015
文章导航
收藏切换

蛋白降解靶向嵌合体(proteolysis-targeting chimera,PROTAC)是一种靶向蛋白质降解的新技术,在生物医药领域受到极大关注。PROTAC分子通过泛素-蛋白酶体系诱导目标蛋白降解能快速、高效地耗竭靶蛋白,并可再次结合底物,实现多次泛素化反应,能一定程度上优化传统小分子表现的剂量依赖性。然而,这种独特化学结构及作用机制也给其体内外药代动力学研究带来诸多挑战,主要包括溶解度不佳、渗透性不好、口服吸收差及生物利用度低等。该文以PROTAC分子的物理化学性质为出发点,分析药代动力学特征,并概述此类药物的生物分析方法,讨论PROTAC技术面临的挑战和前景,为PROTAC药物领域的创新研发及难点突破提供参考。

蛋白降解靶向嵌合体  /  药代动力学  /  生物分析方法

Proteolysis-targeting chimera (PROTAC) is a new technology for targeting protein degradation that has received great attention in the biomedical science community. PROTAC molecules can quickly and efficiently deplete target proteins by inducing degradation of target proteins using the ubiquitin-protease system, and can bind to substrates again to achieve multiple ubiquitination reactions, optimizing the dose dependence and drug resistance of traditional small molecules to a certain extent. However, this unique chemical structure and mechanism of action also brings many challenges to its in vivo and in vitro pharmacokinetic studies, mainly including poor solubility, poor permeability, poor oral absorption, and low bioavailability. Starting from the analysis of the physicochemical properties of PROTAC molecules, this article analyzed the pharmacokinetic characteristics and summarized the bioanalysis methods of such drugs. It also discussed the challenges and prospects of PROTAC technology, providing a reference for innovative research and breakthroughs in the field of PROTAC drugs.

proteolysis-targeting chimera  /  pharmacokinetics  /  bioanalytical methods
王宇昕, 徐智儒. 蛋白降解靶向嵌合体分子药代动力学及其生物分析方法的研究进展. 世界临床药物, 2025 , 46 (5) : 516 -522 . DOI: 10.13683/j.wph.2025.05.015
Yuxin WANG, Zhiru XU. Advances in pharmacokinetics and bioanalytical methods for proteolysis-targeting chimera[J]. World Clinical Drug, 2025 , 46 (5) : 516 -522 . DOI: 10.13683/j.wph.2025.05.015

参考文献 引证文献
排序方式:
[1]
ZENG SX, YE YQ, XIA HY, et al. Current advances and development strategies of orally bioavailable PROTACs[J].Eur J Med Chem, 2023, 261: 115793.
[2]
LI X, SONG YC. Proteolysis-targeting chimera(PROTAC)for targeted protein degradation and cancer therapy[J]. J Hematol Oncol, 2020, 13(1): 50.
[3]
王熙敏, 张程亮, 陈云舟. 靶向蛋白降解技术的特点与研究进展[J]. 中国医院药学杂志, 2023, 43(10): 1170-1175.
[4]
Price E, Weinheimer M, Rivkin A, et al. Beyond rule of five and PROTACs in modern drug discovery: polarity reducers, chameleonicity, and the evolving physicochemical landscape[J]. J Med Chem, 2024, 67(7): 5683-5698.
[5]
GE JX, LI SM, WENG GQ, et al. PROTAC-DB 3.0:an updated database of PROTACs with extended pharmacokinetic parameters[J]. Nucleic Acids Res, 2025,53(D1): D1510-D1515.
[6]
BHUMIREDDY A, BANDARU NVMR, REDDY BR, et al. Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders[J]. Bioorg Med Chem Lett,2022, 55: 128448.
[7]
HAN X, ZHAO LJ, XIANG WG, et al. Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer[J]. J Med Chem, 2021, 64(17):12831-12854.
[8]
KIM GY, SONG CW, YANG YS, et al. Chemical degradation of androgen receptor(AR) using bicalutamide analog-thalidomide PROTACs[J]. Molecules, 2021, 26(9): 2525.
[9]
CECCHINI C, TARDY S, SCAPOZZA L. Linkers as game-changers in PROTAC technology: Emphasizing general trends in PROTAC pharmacokinetics for their rational design[J].Chimia(Aarau), 2022, 76(4): 341-345.
[10]
CANTRILL C, CHATURVEDI P, RYNN C. Fundamental aspects of DMPK optimization of targeted protein degraders[J]. Drug Discov Today, 2020, 25(6): 969-982.
[11]
REJ R K, ALLU S R, ROY J, et al. Orally bioavailable proteolysis-targeting chimeras: an innovative approach in the golden era of discovering small-molecule cancer drugs[J].Pharmaceuticals(Basel), 2024, 17(4): 494.
[12]
WANG YT, PRICE E, FENG M, et al. High-throughput SFC-MS/MS method to measure EPSA and predict human permeability[J]. J Med Chem, 2024, 67(16): 13765-13777.
[13]
ERMONDI G, JIMENEZ DG, SEBASTIANO MR, et al.Rational control of molecular properties is mandatory to exploit the potential of PROTACs as oral drugs[J]. ACS Med Chem Lett, 2021, 12(7): 1056-1060.
[14]
MAPLE HJ, CLAYDEN N, BARON A, et al. Developing degraders: principles and perspectives on design and chemical space[J]. Med Chem Comm, 2019, 10(10): 1755-1764.
[15]
EDMONDSON S D, YANG B, FALLAN C. Proteolysis targeting chimeras(PROTACs) in " beyond rule-of-five"chemical space: recent progress and future challenges[J].Bioorg Med Chem Lett, 2019, 29(13): 1555-1564.
[16]
JIMENEZ DG, SEBASTIANO MR, VALLARO M, et al.IMHB-Mediated chameleonicity in drug design: a focus on structurally related PROTACs[J]. J Med Chem, 2024,67(13): 11421-11434.
[17]
HAN X, WANG C, QIN C, et al. Discovery of ARD-69 as a highly potent proteolysis targeting chimera(PROTAC)degrader of androgen receptor(AR) for the treatment of prostate cancer[J]. J Med Chem, 2019, 62(2): 941-964.
[18]
MARES A, MIAH AH, SMITH IED, et al. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2[J]. Commun Biol, 2020,3(1): 140.
[19]
WEI MM, ZHAO R, CAO YT, et al. First orally bioavailable prodrug of proteolysis targeting chimera(PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo[J]. Eur J Med Chem,2021, 209: 112903.
[20]
ZOU ZF, YANG L, NIE HJ, et al. Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy[J]. Acta Pharmacol Sin, 2024,45(8): 1740-1751.
[21]
YANG WZ, GADGIL P, KRISHNAMURTHY VR, et al. The evolving druggability and developability space: Chemically modified new modalities and emerging small molecules[J].AAPS J, 2020, 22(2): 21.
[22]
VOLAK LP, DUEVEL HM, HUMPHREYS S, et al.Industry perspective on the pharmacokinetic and absorption,distribution, metabolism, and excretion characterization of heterobifunctional protein degraders[J]. Drug Metab Dispos,2023, 51(7): 792-803.
[23]
RICCARDI K, CAWLEY S, YATES PD, et al. Plasma protein binding of challenging compounds[J]. J Pharm Sci, 2015,104(8): 2627-2636.
[24]
SEVERINI LL, BUFALIERI F, INFANTE P, et al.Proteolysis-targeting chimera(PROTAC): Is the technology looking at the treatment of brain tumors?[J]. Front Cell Dev Biol, 2022, 10: 854352.
[25]
KURIMCHAK AM, HERRERA-MONTAVEZ C,MONTSERRAT-SANGRA S, et al. The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells[J]. Sci Signal, 2022, 15(749):eabn2707.
[26]
ZHANG NY, HOU DY, HU XJ, et al. Nano proteolysis targeting chimeras(PROTACs) with anti-hook effect for tumor therapy[J]. Angew Chem Int Ed Engl, 2023, 62(37):e202308049.
[27]
XU KX, WANG Z, XIANG ST, et al. Characterizing the cooperative effect of PROTAC systems with end-point binding free energy calculation[J]. J Chem Inf Model, 2024,64(19): 7666-7678.
[28]
HALLIFAX D, TURLIZZI E, ZANELLI U, et al. Clearance-dependent underprediction of in vivo intrinsic clearance from human hepatocytes: comparison with permeabilities from artificial membrane(PAMPA) assay, in silico and caco-2 assay, for 65 drugs[J]. Eur J Pharm Sci, 2012, 45(5): 570-574.
[29]
GORACCI L, DESANTIS J, VALERI A, et al.Understanding the metabolism of proteolysis targeting chimeras (PROTACs): The next step toward pharmaceutical applications[J]. J Med Chem, 2020, 63(20): 11615-11638.
[30]
XU MS, GU XF, LI C, et al. A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects[J]. Acta Pharmacol Sin, 2024,45(10): 2174-2185.
[31]
ZHANG DL, MA B, DRAGOVICH PS, et al. Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs[J]. Commun Med(Lond), 2024,4(1): 87.
[32]
NGUYEN TTL, KIM JW, CHOI HI, et al. Development of an LC-MS/MS method for ARV-110, a PROTAC molecule, and applications to pharmacokinetic studies[J]. Molecules, 2022,27(6): 1977.
[33]
NIESSEN J, NILSSON JM, PETERS K, et al.Development and validation of LC-MS/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide(ARV-110) and vepdegestrant(ARV-471)[J]. J Pharm Biomed Anal, 2024, 249: 116348.
[34]
WANG Y, WANG ZY, WANG XW, et al. Establishment and validation of a sensitive LC-MS/MS method for the quantification of KRAS G12C protein PROTAC molecule LC-2 in rat plasma and its application to in vivo pharmacokinetic studies of LC-2 PEGylated liposomes[J].Biomed Chromatogr, 2023, 37(6): e5629.
[35]
王鹏伟. PROTACs前体化合物的合成研究[D]. 湘潭: 湘潭大学, 2021.
[36]
KANG LJ, WENG ND, JIAN WY. LC-MS bioanalysis of intact proteins and peptides[J]. Biomed Chromatogr, 2020,34(1): e4633.
[37]
ROY MJ, WINKLER S, HUGHES SJ, et al. SPR-Measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate[J]. ACS Chem Biol, 2019, 14(3):361-368.
[38]
RICHING KM, MAHAN S, CORONA CR, et al. Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action[J]. ACS Chem Biol, 2018, 13(9):2758-2770.
[39]
KOZIOLEK M, AUGUSTIJNS P, BERGER C, et al.Challenges in permeability assessment for oral drug product development[J]. Pharmaceutics, 2023, 15(10): 2397.
[40]
VERMA S, MANNA D. Controlling PROTACs with light[J].Chem Med Chem, 2020, 15(14): 1258-1261.
[41]
LEE M, WU JP, LEE J, et al. A chiral pool strategy for the synthesis of a SMARCA2 degrading PROTAC[J]. Org Pro Res Dev, 2024, 28(4): 1239-1252.
[42]
MALARVANNAN M, RAVICHANDIRAN V, PAUL D.Advances in analytical technologies for emerging drug modalities and their separation challenges in LC-MS systems[J]. J Chromatogr A, 2024, 1732: 465226.
2025年第46卷第5期
48
9
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2025.05.015
  • 接收时间:2024-11-21
  • 首发时间:2026-11-09
  • 出版时间:2025-05-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-11-21
基金
作者信息
    1.中国医药工业研究总院,上海 201203
    2.中国医药工业研究总院,上海医药工业研究院创新药物与制药工艺国家重点实验室,上海 200437
    3.上海市生物物质成药性评价专业技术服务中心,上海 200437

通讯作者:

徐智儒,博士,研究员,研究方向:新药临床前药物代谢动力学、中药药效物质基础研究、毒物相关的筛查及体内外代谢机制研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.05.015
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏